12,013 results match your criteria Ann. Oncol.[Journal]


Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.

Ann Oncol 2020 Jul 4. Epub 2020 Jul 4.

Department of Medical Oncology, Guy's Hospital and Sarah Cannon Research Institute, London, UK.

Background: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patients in small clinical series.

Patients And Methods: KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer (MBC) with prior HER2-targeted therapy and chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.020DOI Listing

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

Ann Oncol 2020 Jul 4. Epub 2020 Jul 4.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Background: Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80mg), a third generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of 160mg osimertinib in BM or LM is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.017DOI Listing

Fusobacterium nucleatum, rectal cancer and radiotherapy.

Ann Oncol 2020 Jul 3. Epub 2020 Jul 3.

Department of Oncology, MRC Oxford Institute for Radiation Oncology, University of Oxford. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.019DOI Listing

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1-4 Inhibitor in Patients with Advanced Solid Tumors.

Ann Oncol 2020 Jul 2. Epub 2020 Jul 2.

Medical Oncology, Sarah Cannon Research Institute and Cancer Institute University College London, London, UK.

Background: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor (FGFR)1-4 inhibitor with potent preclinical activity against tumors harboring FGFR aberrations. This first-in-human, phase 1 dose-escalation trial (NCT02052778) evaluates the safety and pharmacokinetics/pharmacodynamics of futibatinib in advanced solid tumors.

Patients And Methods: Following a standard 3+3 dose-escalation design, eligible patients with advanced solid tumors refractory to standard therapies received 8-200 mg futibatinib thrice weekly (TIW) or 4-24 mg once daily (QD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.018DOI Listing

PD-1 Blockade in Japanese Patients with Acral Lentiginous Melanoma.

Authors:
A N Shoushtari

Ann Oncol 2020 Jul 2. Epub 2020 Jul 2.

Department of Medicine, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.014DOI Listing

Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial.

Ann Oncol 2020 Jun 30. Epub 2020 Jun 30.

School of Medicine, Cardiff University, Cardiff, UK.

Purpose: Concurrent chemoradiation is standard-of-care for patients with squamous cell carcinoma of the anus (SCCA). Poor compliance to chemotherapy, radiotherapy treatment interruptions and unplanned breaks may impact adversely on long-term outcomes.

Methods: The ACT II trial recruited 940 patients with localized SCCA, and assigned patients to mitomycin (week 1) or cisplatin (weeks 1 and 5), with fluorouracil (weeks 1 & 5) and radiotherapy (50·4Gy in 28 fractions over 38 days). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.012DOI Listing

First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient.

Ann Oncol 2020 Jun 29. Epub 2020 Jun 29.

Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, CHU BORDEAUX, F-33000 Bordeaux, FRANCE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323636PMC

Androgen deprivation and SARS-CoV-2 in men with prostate cancer.

Ann Oncol 2020 Jun 29. Epub 2020 Jun 29.

New Children's Hospital, Pediatric Research Center, Helsinki University Hospital, Helsinki, Finland; Stem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323668PMC

Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO Precision Medicine Working Group.

Ann Oncol 2020 May 19. Epub 2020 May 19.

Department of Medicine, Washington University School of Medicine, Washingoton, USA.

Background: The use of next-generation sequencing technologies has enabled the rapid identification of non-synonymous somatic mutations in cancer cells. Neoantigens are mutated peptides derived from somatic mutations not present in normal tissues, that may result in the presentation of tumour-specific peptides capable of eliciting anti-tumour T-cell responses. Personalised neoantigen-based cancer vaccines and adoptive T-cell therapies have been shown to prime host immunity against tumour cells and are under clinical trial development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.008DOI Listing

Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Schilling et al.

Ann Oncol 2015 Jan 4;26(1):251-252. Epub 2019 Dec 4.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdu512DOI Listing
January 2015

Correction to: Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer.

Authors:

Ann Oncol 2011 Nov 4;22(11):2537. Epub 2019 Dec 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdr482DOI Listing
November 2011

Reply to Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer.

Authors:
D Chu Z Zhang Y Li G Ji

Ann Oncol 2011 Nov 4;22(11):2534. Epub 2019 Dec 4.

State Key Laboratory of Cancer Biology, Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdr310DOI Listing
November 2011

Correction to: Chronic lymphocytic leukemia.

Authors:

Ann Oncol 2011 Feb 4;22(2):492. Epub 2019 Dec 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdq725DOI Listing
February 2011

Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol 2020 Jun 25. Epub 2020 Jun 25.

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland and Faculty of Biomedical Sciences, USI, Lugano, Switzerland; Division of Cancer Medicine, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.011DOI Listing

Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors".

Ann Oncol 2015 Feb 7;26(2):445. Epub 2020 Jan 7.

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdu547DOI Listing
February 2015

Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?

Authors:
Nima Sharifi

Ann Oncol 2020 Jun 20. Epub 2020 Jun 20.

Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.009DOI Listing

TRK inhibitors- Managing on-target toxicities.

Authors:
J S J Lim D S P Tan

Ann Oncol 2020 Jun 20. Epub 2020 Jun 20.

National University Cancer Institute, Singapore; Cancer Science Institute, Singapore, National University Singapore; Yong Loo Lin School of Medicine, National University Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.010DOI Listing

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.

Ann Oncol 2020 Jun 20. Epub 2020 Jun 20.

Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA); Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional de Málaga, Spain. Electronic address:

Background: A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de-novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The objective of the study was to determine whether this polymorphism is associated with outcomes for metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.

Patients And Methods: A total of 547 patients treated with abiraterone or enzalutamide from two prospective cohorts were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.006DOI Listing

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.

Ann Oncol 2020 Jun 20. Epub 2020 Jun 20.

Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:

Background: Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer (CRC). Nevertheless, only limited data exist about the role of this bacterium in locally advanced rectal cancer (LARC). In this study, we quantified Fusobacterium nucleatum in untreated and post-neoadjuvant chemo-radiotherapy (nCRT) samples from LARC patients and investigated its association with therapy response and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.003DOI Listing

Response to W.C. Taylor, and C. Fiala and E.P. Diamandis.

Ann Oncol 2020 Jun 19. Epub 2020 Jun 19.

US Oncology Research, US Oncology, The Woodlands, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.008DOI Listing

The forefront of ovarian cancer therapy: update on PARP inhibitors.

Ann Oncol 2020 Jun 19. Epub 2020 Jun 19.

Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Italy.

Background: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.

Design: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.004DOI Listing

Reaching out beyond first-line treatments in advanced biliary tract cancers.

Authors:
A Lamarca J W Valle

Ann Oncol 2020 Jun 19. Epub 2020 Jun 19.

Department of Medical Oncology, The Christie NHS Foundation Trust; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.002DOI Listing

COVID-19 in patients with lung cancer.

Ann Oncol 2020 Jun 16. Epub 2020 Jun 16.

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical Center, New York, NY; Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Background: Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during this pandemic.

Patients And Methods: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n=102) at a single center from March 12-May 6, 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689PMC

Corrigendum to "Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial": Annals of Oncology 2012; 23: 1818-1825.

Ann Oncol 2020 Jun 15. Epub 2020 Jun 15.

First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany; German Hodgkin Study Group, First Department of Internal Medicine, UniversityHospital of Cologne, Cologne, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.020DOI Listing

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.

Ann Oncol 2020 Jun 13. Epub 2020 Jun 13.

Dept. Medical Oncology. Biomedical research Institute Incliva, University of Valencia. Valencia (Spain); CIBERONC. Instituto de Salud Carlos III. Madrid. Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.030DOI Listing

Anti-PD1 checkpoint inhibitor therapy in acral melanoma: A multicentre study of 193 Japanese patients.

Ann Oncol 2020 Jun 6. Epub 2020 Jun 6.

National Cancer Center Hospital, Tokyo, Japan.

Background: Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the real-world efficacy of anti-PD-1 antibodies in advanced AM.

Patients And Methods: We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.031DOI Listing

TEMPORARY REMOVAL: Response to the letter to the editor: "Conceptual and Clinical interpretation of 2007 WCRF/AICR score in relation to cancer-related health outcomes", by Rama Jayaraj, Chellan Kumaraswamy, Greg Raymond, Siddhartha Baxi, Peter Shaw.

Ann Oncol 2020 Jun 6. Epub 2020 Jun 6.

Health Research Institute of the Balearic Islands, University Hospital Son Espases, Palma, Spain.

The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.029DOI Listing

The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer.

Ann Oncol 2020 Jun 5. Epub 2020 Jun 5.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. Electronic address:

Background: Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is still dismal. Alterations in the DNA damage response (DDR) pathways are emerging as novel targets for treatment across different cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.027DOI Listing

Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).

Ann Oncol 2020 Jun 2. Epub 2020 Jun 2.

Department of Medical Oncology, Medical School, University of Ioannina, Greece; Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.023DOI Listing

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

Ann Oncol 2020 Jun 1. Epub 2020 Jun 1.

Saint-Petersburg Scientific Practical Center for Specialized Medical Care, St Petersburg, Russia.

Purpose: We designed an open-label, non-comparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies.

Patients And Methods: From 29 April 2016 to 29 March 2017, 153 patients were randomly assigned (1:1) to either TT-B (n=77) or C-B (n=76). The primary endpoint was progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.024DOI Listing

Reply to the Letter to the Editor 'Aspirin to prevent gastrointestinal cancer - but recent trial data don't fit' by Jacobsen and colleagues.

Ann Oncol 2020 May 31. Epub 2020 May 31.

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.025DOI Listing

What is the value of health-related quality of life in a negative superiority trial?

Ann Oncol 2020 May 30. Epub 2020 May 30.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.022DOI Listing

Prognostic gene expression signature for high-grade serous ovarian cancer.

Ann Oncol 2020 May 28. Epub 2020 May 28.

School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia. Electronic address:

Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.019DOI Listing

Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated with Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial.

Ann Oncol 2020 May 25. Epub 2020 May 25.

Haematology, University College Hospital London, London, UK; UCL Cancer Institute, University College London, UK.

Background: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen.

Patients And Methods: Eligible pts were aged 18-65 years with stage II-IV untreated DLBCL and an International Prognostic Index (IPI) score of 3-5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.016DOI Listing

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.

Ann Oncol 2020 May 25. Epub 2020 May 25.

Breast Cancer Research Centre-WA & Curtin University, Perth, WA, Australia.

Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxis was mandated, grade 3 diarrhea was observed in 40% of patients and 17% discontinued due to diarrhea. The international, open-label, sequential-cohort, phase II CONTROL study is investigating several strategies to improve tolerability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.012DOI Listing

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial - REACHIN.

Ann Oncol 2020 May 25. Epub 2020 May 25.

GE and Digestive Oncology Department, CUB Hôpital Erasme, Brussels, Belgium.

Background: There is a high unmet clinical need for treatments for advanced/metastatic biliary tract cancers (BTC) after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies.

Patients And Methods: REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase 2 study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic BTC that progressed after gemcitabine/platinum chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.018DOI Listing

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.

Ann Oncol 2020 May 24. Epub 2020 May 24.

Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

Background: Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity in preclinical models.

Patients And Methods: This was a phase I study of tucatinib with trastuzumab, without chemotherapy, in patients with progressive, measurable HER2-positive brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.014DOI Listing

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

Ann Oncol 2020 May 24. Epub 2020 May 24.

German Breast Group, Neu-Isenburg, Germany.

Background: The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast cancer (TNBC) is currently not known, either for immune checkpoint blockade (ICB) or conventional chemotherapy.

Patients And Methods: We obtained both whole exome sequencing and RNA-Seq data from pretreatment samples of 149 TNBC of the recent neoadjuvant ICB trial, GeparNuevo. In a predefined analysis, we assessed the predictive value of TMB and a previously developed immune GEP for pathological complete remission (pCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.015DOI Listing

Tackling diversity within diversity.

Ann Oncol 2020 May 23. Epub 2020 May 23.

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.013DOI Listing

Are we ready to accept intermediate outcome measures in clinical cancer trials?

Authors:
V Grünwald E Calvo

Ann Oncol 2020 May 23. Epub 2020 May 23.

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.017DOI Listing

Re: Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.

Authors:
B A Mahal

Ann Oncol 2020 Jul 21;31(7):829. Epub 2020 May 21.

Dana-Farber Cancer Institute McGraw/Patterson Center for Population Sciences, University of Miami Miller School of Medicine, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.010DOI Listing

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

Ann Oncol 2020 May 19. Epub 2020 May 19.

Division of Genetics and Epidemiology, Institute of Cancer Research, London; National Cancer Registration and Analysis Service, Public Health England, Wellington House, London; Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

Background: Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival.

Patients And Methods: We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237184PMC
May 2020
7.040 Impact Factor

Reply to 'Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?' by Evesque et al.

Ann Oncol 2020 May 18. Epub 2020 May 18.

Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; Comprehensive Cancer Center Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.007DOI Listing